It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GNPX’s FA Score shows that 0 FA rating(s) are green whileOCS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GNPX’s TA Score shows that 3 TA indicator(s) are bullish while OCS’s TA Score has 5 bullish TA indicator(s).
GNPX (@Biotechnology) experienced а -0.97% price change this week, while OCS (@Biotechnology) price change was +6.73% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.91%, and the average quarterly price growth was -1.42%.
GNPX is expected to report earnings on May 29, 2024.
OCS is expected to report earnings on Feb 28, 2023.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
GNPX | OCS | GNPX / OCS | |
Capitalization | 8.68M | 732M | 1% |
EBITDA | N/A | N/A | - |
Gain YTD | -88.913 | 55.387 | -161% |
P/E Ratio | N/A | 63.06 | - |
Revenue | N/A | N/A | - |
Total Cash | 21M | N/A | - |
Total Debt | 279K | N/A | - |
GNPX | ||
---|---|---|
OUTLOOK RATING 1..100 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 41 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 95 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX | OCS | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago46% |
Stochastic ODDS (%) | 2 days ago84% | 2 days ago33% |
Momentum ODDS (%) | 2 days ago90% | 2 days ago54% |
MACD ODDS (%) | 2 days ago86% | 2 days ago64% |
TrendWeek ODDS (%) | 2 days ago90% | 2 days ago49% |
TrendMonth ODDS (%) | 2 days ago90% | 2 days ago55% |
Advances ODDS (%) | 6 days ago80% | 2 days ago69% |
Declines ODDS (%) | 2 days ago90% | 9 days ago60% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago36% |
Aroon ODDS (%) | 2 days ago90% | 2 days ago55% |
A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with HURA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then HURA could also see price increases.
Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
---|---|---|---|---|
GNPX | 100% | -2.86% | ||
HURA - GNPX | 60% Loosely correlated | +5.80% | ||
REVB - GNPX | 48% Loosely correlated | -3.33% | ||
TYRA - GNPX | 33% Poorly correlated | +1.06% | ||
HOWL - GNPX | 33% Poorly correlated | -1.20% | ||
ENSC - GNPX | 31% Poorly correlated | -0.78% | ||
More |
A.I.dvisor indicates that over the last year, OCS has been loosely correlated with HURA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if OCS jumps, then HURA could also see price increases.
Ticker / NAME | Correlation To OCS | 1D Price Change % | ||
---|---|---|---|---|
OCS | 100% | +2.05% | ||
HURA - OCS | 35% Loosely correlated | +5.80% | ||
CUE - OCS | 26% Poorly correlated | +3.92% | ||
SNSE - OCS | 25% Poorly correlated | +11.97% | ||
ONCO - OCS | 25% Poorly correlated | +11.90% | ||
GNPX - OCS | 24% Poorly correlated | -2.86% | ||
More |